Full-Time

Director – And Execution Lead

Launch Preparedness, Policy & Advocacy Strategy

Posted on 7/6/2026

Deadline 7/21/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$230.9k - $384.8k/yr

No H1B Sponsorship

Remote in USA + 1 more

More locations: New York, NY, USA

Remote

Remote within the United States; occasional travel up to 40%.

MD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • MD/DO degree required and 5+ years of relevant experience
  • Demonstrated success operating with enterprise or national accountability and influencing outcomes across highly matrixed organizations
  • Deep expertise in U.S. vaccine policy, ACIP processes, medical society engagement, and payer and coverage landscapes
  • Proven ability to lead complex, high‑visibility, and policy‑sensitive initiatives through influence and governance, without direct people management responsibility
  • Experience serving as a strategic advisor to senior and executive leadership, including VP‑level stakeholders
  • Strong strategic mindset with the ability to operate effectively in ambiguity and translate complexity into clear enterprise direction and executional standards
  • Excellent written and verbal communication skills, with demonstrated success engaging senior internal and external stakeholders
  • Ability to travel up to 40 percent, including overnight travel, and comply with Pfizer corporate travel policies and procedures
Responsibilities
  • Set and govern national launch preparedness strategy and operating standards for priority U.S. vaccine and drug launches, with an initial focus on the Lyme Vaccine (LB6V) and flexibility to support additional assets as portfolio priorities evolve
  • Define, maintain, and govern enterprise‑wide launch readiness standards, success metrics, and policy‑related readiness expectations for Vaccines Field Medical, ensuring consistent application across assets and field teams
  • Serve as the escalation authority for policy‑driven risks and access barriers that may impact launch timing, uptake, or sustainability, providing strategic recommendations and decision support to U.S. Medical Affairs and Commercial leadership
  • Partner with HQ Brand Medical leads and cross‑functional stakeholders, including Commercial, Operations, Medical Analytics, and Vaccines Field Medical leadership, to anticipate and shape national field deployment models, engagement priorities, and enablement strategies, without duplicating asset‑level strategy ownership
  • Provide enterprise oversight and strategic direction for Pre‑Approval Information Exchange (PIE) readiness and execution, ensuring consistent governance, insight synthesis, and readiness expectations across launches
  • Leverage enterprise‑level medical insights, analytics, and engagement data to continuously refine launch preparedness frameworks and optimize field medical effectiveness at scale
  • Provide strategic oversight and direction for the development and deployment of launch‑related training, playbooks, and field readiness materials, ensuring alignment with enterprise standards and policy‑informed engagement expectations
  • Ensure scalable, repeatable, and policy‑integrated launch preparedness approaches are applied across pipeline and in‑line assets, rather than asset‑specific or ad hoc execution models
  • Lead and shape enterprise field medical engagement across national organizations, including ACOG, AAP, IDSA, ACP, AAFP, and other relevant professional societies, governing engagement frameworks rather than executing all interactions directly
  • Act as a strategic bridge between HQ and Field Medical teams, ensuring bidirectional communication, enterprise alignment, and executional clarity related to launch, policy, and advocacy strategy
  • Influence Scientific Engagement Leads, Field Medical society leads, and Field Medical stakeholders through subject‑matter expertise, strategic guidance, and escalation authority, rather than formal people leadership
  • Establish and reinforce enterprise standards and guidance for policy‑related field medical messaging and engagement approaches, ensuring consistency and confidence across teams and assets
  • Incorporate field feedback, external insights, and evolving policy dynamics to continuously refine enterprise launch preparedness and advocacy execution frameworks
Desired Qualifications
  • Prior experience supporting U.S. vaccine or specialty product launches, including pre‑approval readiness and cross‑functional field enablement
  • Experience working closely with or engaging U.S. medical societies, guideline‑setting bodies, or policy‑influencing organizations

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • 4 August 2026 guidance rose to $60.5 billion-$62.5 billion on non-COVID growth.
  • Eliquis delivered $2.43 billion in Q2 2026, up 19%, offsetting COVID declines.
  • Additional $2.5 billion savings from 2027-2029 supports margins and cash returns.

What critics are saying

  • Eliquis faces patent pressure by 2028, threatening Pfizer's largest current revenue engine.
  • Pfizer cut Catania 370 jobs on 7 July 2026, signaling restructuring pain.
  • COVID sales keep shrinking; low Paxlovid demand and Comirnaty seasonality expose a weak base.

What makes Pfizer unique

  • Pfizer's 2026 scale spans Eliquis, Padcev, Prevnar 20, and Comirnaty globally.
  • July 2026 Padcev-Keytruda approval deepens Pfizer's oncology franchise beyond COVID dependence.
  • Pfizer's manufacturing and distribution reach lets Québec, hospitals, and governments adopt products quickly.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.

Yahoo Finance
Aug 4th, 2026
Pfizer Q2 earnings beat at 77¢/share, revenue guidance raised to $62.5B on non-COVID growth

Pfizer reported second-quarter revenue of $15.03 billion and raised its full-year revenue guidance to $60.5 billion to $62.5 billion, up from a previous range of $59.5 billion to $62.5 billion. Adjusted earnings reached 77 cents per share, beating the 68-cent consensus estimate. Revenue growth was led by Eliquis, which rose 19% operationally, and Padcev, which climbed 23%. Paxlovid fell 95% amid lower COVID-19 infection rates, whilst Comirnaty declined 34%. Excluding COVID products, revenues grew 5% operationally. The company announced an additional $2.5 billion in cost savings expected from 2027 through 2029. CFO Dave Denton is departing on 15 August, with Cecile Guegan stepping in as interim CFO. Pfizer shares rose 1.8% to $25.50 in premarket trading.

Yahoo Finance
Aug 3rd, 2026
Pfizer returned $49B to shareholders but stock fell 21% over five years

Pfizer returned $49 billion to shareholders over five years through dividends and buybacks, equal to 34% of its current market value. Despite this substantial cash distribution, the stock delivered a -21% total return whilst the S&P 500 gained 81% over the same period. The pharmaceutical giant generated the payouts from a $63 billion business with a 25% operating margin. Of the total returned, $47 billion came from dividends and $2 billion from share repurchases. Management has affirmed its commitment to maintaining and growing dividends whilst reducing leverage. However, the company faces a "patent cliff" with $14-15 billion in annual revenue at risk from loss of exclusivity. Revenue growth stands at just 1.4% over the last twelve months, raising concerns that heavy payouts reflect fewer high-return reinvestment opportunities as core growth engines slow.

INACTIVE